Abstract
With the global coronavirus disease 2019 (COVID-19) pandemic, there is an urgent need for risk stratification tools to support prevention and treatment decisions. The Centers for Disease Control and Prevention (CDC) listed several criteria that define high-risk individuals, but multivariable prediction models may allow for a more accurate and granular risk evaluation. In the early days of the pandemic, when individual level data required for training prediction models was not available, a large healthcare organization developed a prediction model for supporting its COVID-19 policy using a hybrid strategy. The model was constructed on a baseline predictor to rank patients according to their risk for severe respiratory infection or sepsis (trained using over one-million patient records) and was then post-processed to calibrate the predictions to reported COVID-19 case fatality rates. Since its deployment in mid-March, this predictor was integrated into many decision-processes in the organization that involved allocating limited resources. With the accumulation of enough COVID-19 patients, the predictor was validated for its accuracy in predicting COVID-19 mortality among all COVID-19 cases in the organization (3,176, 3.1% death rate). The predictor was found to have good discrimination, with an area under the receiver-operating characteristics curve of 0.942. Calibration was also good, with a marked improvement compared to the calibration of the baseline model when evaluated for the COVID-19 mortality outcome. While the CDC criteria identify 41% of the population as high-risk with a resulting sensitivity of 97%, a 5% absolute risk cutoff by the model tags only 14% to be at high-risk while still achieving a sensitivity of 90%. To summarize, we found that even in the midst of a pandemic, shrouded in epidemiologic "fog of war" and with no individual level data, it was possible to provide a useful predictor with good discrimination and calibration.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
G.N.R. reports grants from Israel Science Foundation, grants from Israel-US Binational Science Foundation, grants from European Research Council, grants from Amazon Research Award during the conduct of the study. U.S. reports personal fees from K-health, outside the submitted work.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data availability Access to the data used for this study can be made available upon request, subject to an internal review by N.B. and N.D. to ensure that participant privacy is protected, and subject to completion of a data sharing agreement, approval from the institutional review board of Clalit Health Services and institutional guidelines and in accordance with the current data sharing guidelines of Clalit Health Services and Israeli law. Pending the aforementioned approvals, data sharing will be made in a secure setting, on a per-case-specific manner, as defined by the chief information security officer of Clalit Health Services. Please submit such requests to N.D. (noada@clalit.org.il). Code availability The analytic code required to produce the COVID-19 model predictions is available at: https://github.com/clalitresearch/COVID-19-Model
